Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/EXELIXIS-INC-9235/news/Exelixis-Inc-Featured-Company-News-Exelixis-Cabozantinib-Met-Primary-Endpoint-in-Phase-3-CELE-25307083/?utm_source=whatsapp&utm_medium=social&utm_campaign=share